How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Gamma Knife Treatment Market
- By Application: Brain Tumors, Arteriovenous Malformations (AVMs), Trigeminal Neuralgia, Acoustic Neuroma, Pituitary Tumors, Metastatic Brain Cancer
- By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Cancer Treatment Centers
- By Technology: Leksell Gamma Knife, Perfexion Gamma Knife, Icon Gamma Knife
- By Procedure Type: Single-session Radiosurgery, Fractionated Radiosurgery
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Brain Tumors leads By Application at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 11 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 261 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.161 →
- 11 Company Profiles 11 players: SWOT & benchmarking p.169 →
Full report · locked preview
Everything inside the Gamma Knife Treatment Market report
A complete, evidence-based study - 11 chapters and 109 sections covering market size, segmentation across 4 axes, regional analysis and 11 company profiles, forecast to 2033.
Segmentation covered
Application 6
End User 4
Technology 3
Procedure Type 2
Companies profiled
Elekta AB
Varian Medical Systems (a Siemens Healthineers company)
Accuray Incorporated
Brainlab AG
Masep Medical Technology Co. Ltd.
Siemens Healthineers
Philips Healthcare
Medtronic plc
Canon Medical Systems Corporation
Hitachi Ltd.
Toshiba Medical Systems Corporation
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
11 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Elekta AB
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Varian Medical Systems (a Siemens Healthineers company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Accuray Incorporated
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Brainlab AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Masep Medical Technology Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Siemens Healthineers
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Philips Healthcare
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Medtronic plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Canon Medical Systems Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Hitachi Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Toshiba Medical Systems Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,345M by 2033 · 4.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Brain Tumors25.1
- Arteriovenous Malformations (AVMs)19.0
- Trigeminal Neuralgia14.4
- Acoustic Neuroma11.9
- Pituitary Tumors20.4
- Metastatic Brain Cancer9.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,205M → $1,916M · 6.0%
Europe$839.8M → $1,106M · 3.5%
Asia Pacific$766.7M → $1,223M · 6.0%
Latin America$474.6M → $748.0M · 5.8%
Middle East and Africa$365.1M → $554.7M · 5.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.822026
4.832027
4.862028
4.872029
4.882030
4.892031
4.902032
4.912033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Elekta AB24.1
- Varian Medical Systems (a Siemens Healthineers company)18.2
- Accuray Incorporated7.5
- Brainlab AG5.5
- Masep Medical Technology Co. Ltd.4.5
- Siemens Healthineers12.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Application30.5%
End User26.0%
Technology15.4%
Procedure Type28.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.5
- Europe19.9
- Asia Pacific22.0
- Latin America13.5
- Middle East and Africa10.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Elekta AB | 97 | 98 | 86 | 95 | 97 | 98 | 95 |
| Varian Medical Systems (a Siemens Healthineers company) | 69 | 83 | 79 | 72 | 81 | 75 | 77 |
| Accuray Incorporated | 88 | 78 | 79 | 71 | 68 | 65 | 75 |
| Brainlab AG | 57 | 63 | 72 | 65 | 65 | 63 | 64 |
| Masep Medical Technology Co. Ltd. | 62 | 56 | 75 | 51 | 69 | 75 | 65 |
| Siemens Healthineers | 59 | 60 | 60 | 71 | 59 | 60 | 62 |
| Philips Healthcare | 42 | 60 | 55 | 55 | 42 | 55 | 52 |
| Medtronic plc | 37 | 57 | 57 | 58 | 39 | 57 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Elekta AB
- Varian Medical Systems (a Siemens Healthineers company)
- Accuray Incorporated
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Elekta AB | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Varian Medical Systems (a Siemens Healthineers company) | − | ✓ | ◐ | ◐ | ✓ | ◐ |
| Accuray Incorporated | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Brainlab AG | ◐ | ✓ | ◐ | − | ✓ | − |
| Masep Medical Technology Co. Ltd. | ◐ | ◐ | ◐ | − | ◐ | ✓ |
| Siemens Healthineers | − | ◐ | − | ◐ | − | ◐ |
| Philips Healthcare | ◐ | − | − | − | ◐ | ◐ |
| Medtronic plc | ◐ | ◐ | ◐ | ◐ | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Elekta AB95
2Varian Medical Systems (a Siemens Healthineers company)77
3Accuray Incorporated75
4Masep Medical Technology Co. Ltd.65
5Brainlab AG64
6Siemens Healthineers62
7Philips Healthcare52
8Medtronic plc51
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Elekta AB
Challenger2
Strong scale, closing on the leaders.
Varian Medical Systems (a Siemens Healthineers company)Accuray Incorporated
Contender3
Focused players with pockets of strength.
Brainlab AGMasep Medical Technology Co. Ltd.Siemens Healthineers
Niche2
Specialists in a single segment or region.
Philips HealthcareMedtronic plc
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Application in North America, then scale across Gamma Knife Treatment Market — a $73M beachhead inside a $1.08B market.
Beachhead (SOM)$73Mobtainable near-term
Serviceable (SAM)$415Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Brain Tumors
Best fit — highest urgency & budget in Application.
Economic buyer80 fit
Arteriovenous Malformations (AVMs)
Strong fit — clear ROI and a fast path to value.
End user66 fit
Trigeminal Neuralgia
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Application in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel26%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Application leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Gamma Knife Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified23%
Evaluation13%
Closed-won8%
$11.4KCAC
$59KLTV
5.2:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Gamma Knife Treatment Market is a high-growth opportunity — $4.55B by 2033, compounding at 11.0%.
TAM · 2025$1.98Btoday
TAM · 2033$4.55Bforecast
CAGR11.0%2027–2033
Cumulative$28.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.55BTotal addressable market
SAM$1.71BServiceable available market
SOM$282MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.0% CAGR
Demand compounds through 2033, outpacing GDP across Application.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Application moving from early to mainstream — durable secular demand.
Consolidation upside
11+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.55BLarge & growingTAM by 2033 at 11.0% CAGR
$1.71BServiceable nowreachable with today’s model
$282MBeachhead winobtainable near-term share
11+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.55BBear7.1% CAGR
$4.55BBase11.0% CAGR
$5.82BBull14.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Gamma Knife Treatment Market — a $7.91B market by 2033. Plan: grow share from 10.0% to 15.5%.
Market size · 2033$7.91Btotal addressable
Market CAGR6.3%2027–2033
Target share15.5%from 10.0% today
Revenue ambition$1.23Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.0% | 15.5% | On track |
| Revenue | $714M | $1.23B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 32.1% | 42.8% | On track |
| Customer retention | 88.5% | 94.5% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Application
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Application share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $181M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Application leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Gamma Knife Treatment Market conversation — a $761M market you can size, segment and defend in minutes.
Market size · 2033$761Mtotal opportunity
Growth6.3%CAGR to 2033
Addressable buyers1,457+accounts in scope
Typical ROI7.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Application
Goal Grow share in Application
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.5×return on cost, year one
< 3 mopayback period
$64K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
11+players profiled in this market
Coverage includes
Elekta ABVarian Medical Systems (a Siemens Healthineers company)Accuray IncorporatedBrainlab AGMasep Medical Technology Co. Ltd.Siemens HealthineersPhilips HealthcareMedtronic plc+3 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Gamma Knife Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Gamma Knife Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Gamma Octalactone (CAS 104 50 7) Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportGamma Probe Devices Market
Market size, share, segmentation and regional forecast.
$563M market · 2025 base year
View reportGamma Radiation Monitoring System Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportGamma Ray Detector Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportGamma Ray Imaging System Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportGamma Ray Monitoring System Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportGamma Ray-based Robots Market
Market size, share, segmentation and regional forecast.
$708M market · 2025 base year
View reportGamma Rays Collimator Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportGamma Spectrometers Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportGamma Sterilization Equipment Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportGamma Valerolactone and Butyrolactone Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportGamma-aminobutyric Acid Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.